rheumatologists come across patients with arthritis with concomitant HBV or HCV in their daily practice. This study describes our experience with patients with arthriris with concurrent chronic HBV infection in 10 patients and HCV infection in 10 patients who received biological agents. in Saudi Arabia.
Material and Methods
Acute HBV infection is defined by the presence of hepatitis B surface antigen (HBsAg), high titers of class-M immune-globulin (IgM) antibodies against the core antigen (i.e., IgM anti-hepatitis B core [HBc] ), and abnormal levels of aminotransferases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST] ). Chronic HBV infection is defined by the persistence of the virus in the host's blood circulation for more than six months (HBsAg-positive). However, these virologic conditions may change during immunosuppression (2, 4, 11) . The presence of chronic HCV infection is confirmed in patients with anti-HCV antibodies by using more sensitive molecular nucleic acid testing methods like polymerase chain reaction, with which the quality and the quantity of HCV-RNA is calculated (12) .
We retrospectively reviewed the medical records of all arthritis patients with HBV or HCV infection who received biological therapy during the course of their disease in four medical centers in Saudi Arabia: King Faisal Specialist Hospital and Research Center, King Fahd Hospital, and King Abdulaziz University Hospital in Jeddah, and King Khalid University Hospital in Riyadh. We reviewed the charts of patients with arthritis and viral hepatitis on biological therapy from time period of their rheumatic disease onset until last outpatient visit up to November 2015. We obtained approval from the institutional ethics review board for the research protocol in all four centers. Being a retrospective study, consent was not obtained from the patients.
We included all patients above 13 years of age with the following features: confirmed clinical diagnosis of autoimmune rheumatic disease by a qualified rheumatologist and confirmed diagnosis of HBV or HCV by serological and molecular methods. HBV reactivation is defined as the reappearance of an active necro-inflammatory disease in a person known to have an inactive HBsAg carrier state or resolved HBV infection. HCV relapse is defined as a reappearance of serum HCV-RNA after end of HCV treatment. We excluded children younger than 13 years of age, hepatitis cases not linked to HBV or HCV, and HCV antibodies positive but HCV-RNA negative patients. 
Results
We identified 20 patients with viral hepatitis and arthritis that were on biological therapy, including 10 patients with HBV infection (Table 1) and 10 patients with HCV infection (Table 2 ).
In the HBV infection group (Table 2) , the mean age was 51 (34-85) years and 80% were females. Eight (80%) HBV patients had rheumatoid arthritis (RA), one patient (10%) had RA/ systemic lupus erythematosus, and one patient (10%) had human immunodeficiency virus related-arthritis (Table 3) . Seven (70%) HBV patients were in chronic inactive HBsAg carrier states with undetectable HBV-DNA, and three HBV patients (30%) had chronic active hepatitis B with HBV-DNA of >2000 IU/mL and mild elevation of transaminases in one of them.
Antiviral therapies were given to nine (90%) of the HBV patients on biological therapy. Entecavir was given to seven patients, lamivudine followed by entecavir was given to 1 patient, and tenofovir was given to 1 patient (Table 3) . One patient who was HBsAg-positive, anti-HBs-positive, anti-HBe-positive, and had undetectable HBV-DNA was not given antiviral therapy. The majority (80%) of HBV patients received a biological treatment consisting of etanercept (ETA) (8 episodes), adalimumab (ADA) (3 episodes), tociluzumab (TOC) (Actemra; Genetech, USA) (1 episode), and rituximab (RIT) (Mabthera; Genetech, USA) (1 episode). Synthetic disease-modifying antirheumatic drugs (s-DMARDs) were prescribed in all except one (with missing data) and consisted of methotrexate (9 episodes), sulfasalazine (4 episodes), hydroxychloroquine (8 episodes), azathioprine (1 episode), mycophenolate (1 episode), and cyclophosphamide (1 epi- Table 2 . Patients characteristics of 10 arthritis patients with Hepatitis C infection on biologics (Table 3 ).
The mean age in HCV group (Table 3) was 54 (23-79) years and all were female RA patients. Three had detectable HCV-RNA before the start of biologics. Nine HCV patients received antiviral treatment in the form of pegylated interferon (PEG-INF) and ribavirin (RIB), and seven patients had sustained virologic responses (SVR) before the start of biological treatment. Three patients had detectable HCV-RNA during the course of biological therapy. One of the three patients was a non-responder, and two patients were relapsers. One of the relapsers received direct acting antiviral treatment (DAAT) in the form of sofosbuvir and RIB and achieved sustained SVR. All patients with SVR and relapsers received biologics. The responders in the HCV group had undetectable HCV-RNA and normal liver transaminases during biological treatments. Also, the relapsers had stable liver function tests and enzymes in spite of persistent elevation of HCV-RNA ( Table 3 ). The biologics used were ETA, ADA, TOC, RIT, abatacept (Orencia; Bristol-Myers Squibb, USA) (ABA), and INF. The duration of the follow-up was 54 (36-72) months. The s-DMARDs used were methotrexate (7 episodes), leflunomide (2 episodes), sulfasalazine (3 episodes), hydroxychloroquine (4 episodes), gold (1 episode), and cyclosporine (1 episode). Steroids were used in six patients. Multiple biologics were used in five of the patients with arthritis in the HCV group.
Discussion
Hepatitis B and HCV infections are considered serious worldwide public health problems. According to the World Health Organization (WHO), as of 2010 around 1 million annual deaths occurred due to viral hepatitis infections (13). Abdo (7) showed that in 2007, viral hepatitis ranked as the second most common viral infection in Saudi Arabia, with around 9,000 newly diagnosed cases reported (52% with HBV, 32% with HCV, and 16% with hepatitis A virus). The WHO (13) has reported that viral hepatitis infections are the leading cause of liver cancer in the world, accounting for 78% of cases. Reactivation of viral hepatitis infection presents a concern associated with the increasing use of biological agents to treat arthritis and other conditions. However, our results showed only two of ten (20%) patients had persistently mild elevation of HBV at less than 2000 IU/mL that was present even before the start of biological therapy; had no further elevation of transaminases during follow-up at 72 months and 60 months with antiviral therapy. In both patients, ETA was used as biological therapy. One patient with RA and resolved HBV infection (HBsAg-negative, HBc-antibody-positive and HBs-antibody-positive and undetectable HBV-DNA) treated with TOC was not given antiviral therapy. During follow-up at 27 months, no increase in transaminases or in the viral load was noted in this patient. Three of ten patients in the HCV group (30%), (two HCV relapsers, and one patient who did not complete the PEG-INF treatment because of side effects) continued to have normal liver function tests Multiple biologics (n)% 3 (30) and enzymes in spite of persistent elevation of HCV-RNA. All three patients were genotype 4, which is the common genotype in Saudi Arabia (14) and has been shown by Sarasin-Filipowicz (15) to be resistant to interferon-based regimens.
The American College of Rheumatology (ACR), the American Gastroenterology Association (AGA) and the American Association for the Study of Liver Diseases (AASLD) recommend that all patients that need biologics and other immunosuppressive therapy should be screened for HBsAg (16) (17) (18) . If there is evidence of past or present HBV infection, the quantitative HBV-DNA viral load should be determined and prophylactic antiviral therapy should be given. The ACR (16) and AASLD (18) recommend that patients with resolved HBV infection (i.e., HBc-antibody-positive, normal liver function tests, HBc-antibody-positive, and HBsAg-negative) should receive the same biological treatment as unexposed patients as long as the patient's viral load is monitored regularly (i.e., at least every 6-12 months). The AGA classifies immunosuppressive therapy into low-, moderate-, or high-risk groups based on estimates of reactivation and the available evidence (17) . Rituximab is categorized in the high-risk group defined by expected incidence of HBV reactivation in >10% of HBsAg-positive/HBc-antibody-positive or HBsAg-negative/HBc-antibody-positive patients. ETN, ADA, certolizumab, IFX, ABA, and ustekinumab are categorized in the moderate-risk group, with an expected incidence of reactivation in 1-10% of patients. The AGA suggests antiviral prophylaxis for patients at moderate risk of reactivation undergoing immunosuppressive drug therapy and biological therapy rather than monitoring and that antivirals should be continued for six months after the cessation of immunosuppressive therapy.
To date, few studies have been carried out in rheumatic disease patients with previous HBV infection treated with anti-TNF (11, 19) . A review by Xuan et al. (19) of all cases published in the literature up to 2012 identified 25 HBsAg-positive patients suffering from rheumatic disease treated by anti-TNF without antiviral prophylaxis. HBV reactivation occurred in 13 cases, including three cases that resulted in fulminant hepatitis, one death, and one liver transplantation, which may alternatively have been related to Still' s disease or an idiopathic drug reaction. In the previous stated study , one patient reported with HBV reactivation after the third infusion of infliximab required drug withdrawal, and the patient was treated with entecavir for three months, which decreased ALT levels to normal (19) . However, infliximab is associated with a greater risk of reactivation of HBV in HBsAg-positive patients compared with etanercept or adalimumab. The risk of HBV reactivation in HBsAg-negative/anti-HBc-positive patients is low. In a literature review, Vigano (20) showed a total of 214 patients suffering from rheumatological disorders or IBD with HBsAg-negative/HBc-antibody-positive carriers were treated with IFX, ETN, and ADA. In only three cases with reported HBV reactivation followed by a hepatitis flare-up, the drug was withdrawn and antiviral medication started. The currently recommended protocol includes prophylaxis with lamivudine of all inactive carriers (HBsAg negative HBc antibody positive patients) during therapy and for 6-12 months following therapy with TNF-α inhibitors and quarterly monitoring of HBsAg. (2 ,18) . A prospective study by Caporali et al. (21) of fewer than 100 patients with occult HBV infection (HBc-antibody-positive without HBsAg) showed no HBV reactivation with anti-TNF therapy. Reactivation of occult HBV infection has been observed in patients treated with RTX by Gigi et al. (22) and ABA by De Nard et al. (23) . Several other studies reported reactivation in both rheumatic and non-rheumatic patients by biological therapy (24) (25) (26) (27) (28) (29) (30) .
In the context of HCV infection, the risk of flareup during anti-TNF treatment is controversial. In a comprehensive literature review conducted by Pompili et al. (6) between January 2000 and August 2013, a total of 216 patients with HCV were observed for a cumulative total of 260 patients / years of anti-TNF treatment. Only three cases of drug withdrawal due to suspected worsening of HCV liver were reported. Short-term use of anti-TNF appears safe, but insufficient long-term safety data exist. The authors studied 153 patients on etanercept observed for a median duration of 1.14 years. Three cases showed elevation of ALT/AST, five cases reported elevation of HCV-RNA, and two cases withdrew the drug due to toxicity. Forty patients were on infliximab, including two reported cases with elevation of AST/ALT and four cases with elevation of HCV-RNA. One of those patients withdrew drug therapy due to liver toxicity. The last group of 23 patients was on ADA with no complications (6) .
With the availability of highly effective antiviral treatments for HCV, rheumatologists should collaborate with the hepatologists to determine if the patient is a candidate for antiviral treatment. The EASL and the AASLD-IDSA recommend that the new interferon-free regimes of HCV with directly acting antiviral therapy have minimal toxicity and side effects, with reported cure rates of 93-100% in all HCV genotypes (12, 31) . Biologics such as anti-TNF and RTX have been usefully employed without significant side effects in HCV-RNA-positive RA patients (32) (33) (34) . The limitations of this study include the retrospective nature of the study and the small number of patients due to the rarity of patients diagnosed with arthritis and hepatitis B/C infection requiring biologic theraphy. Well-designed prospective studies are required to confirm the safety of biological therapy in this subset of patients.
In conclusion, patients with arthritis with concomitant HBV or HCV infections commonly present to rheumatologists. Given the risk of reactivation or relapse during or after the use of biological treatment, screenings should be undertaken for all patients. Patients with active HBV infections as well as chronic inactive carriers should be monitored regularly and prophylactic antiviral therapy started. Due to the lack of sufficient prospective studies demonstrating the rate of HCV flare-up on biological therapy, caution should be exercised and careful monitoring of liver enzymes and viral load is mandated in vulnerable HCV-RNA patients. However, the risk of HCV relapse does not preclude the use of biologics. The new directly DAAT may be more effective in reaching SVR of HCV-RNA in all genotypes. Treatment of the complex combination of rheumatic disease and viral hepatitis should be individualized by rheumatologists in collaboration with hepatologists to minimize mortality and morbidity.
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